66th ASH Annual Meeting: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis

Symposia: Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Fundamental Science, Adult, Combination therapy, Translational Research, Elderly, Clinical Research, Genomics, Hematopoiesis, Diseases, Immune mechanism, Treatment Considerations, Immunology, Metabolism, Myeloid Malignancies, Biological Processes, Technology and Procedures, Molecular biology, Human, Study Population, Pathogenesis, Molecular testing, Omics technologies

Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

Moderators:

Vanessa E. Kennedy, MD, University of California- San Francisco and Sarah Skuli, MD, PhD, Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

637

Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment

Susan DeWolf, MD¹, Nicholas Ceglia, PhD²^*, Matthew Zatzman, PhD³^*, Brianna Gipson⁴^*, Yuval Elhanati, PhD⁵^*, Zoe Katsamakis⁶^*, Hannah Lees, PhD³^*, Kenyon Weis⁷^*, Gustavo Yepes⁸^*, Barbara Oliveira⁸^*, Ana Figueiredo Longhini⁸^*, Natalie Grier Smith, BA⁹^*, Katherine Nichols⁴^*, Eliyahu Havasov³^*, Karen Zhao⁸^*, Brigita Meskauskaite⁸^*, Ignas Masilionis⁸^*, Alexander M. Lewis⁷^*, Maria Adriana Cuibus⁸^*, M. Kazim Pajwani, PhD⁸^*, Simone A Minnie, PhD¹⁰, Ronan Chaligne, PhD¹¹^*, Andri Leo L Lemarquis, MD, PhD⁴^*, Aaron D. Goldberg¹², Katharine C. Hsu, MD, PhD⁴, Eytan M. Stein, MD¹³, Benjamin D. Greenbaum, PhD³^*, Omar Abdel-Wahab, MD¹, Sohrab P. Shah, PhD²^* and Marcel R.M. van den Brink, MD, PhD¹⁴

¹Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
³Computational Oncology, Memorial Sloan Kettering Cancer Center, New York
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Computational Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
⁶Department of Pediatrics, Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Memorial Sloan Kettering Cancer Center, New York
⁹Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
¹¹Single Cell Analytics and Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Department of Medicine; Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
¹⁴Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

4:45 PM

638

Dysregulation of Developmental Transcription Factors in Acute Myeloid Leukemia Predicts Poor Outcome and Impacts Adaptive Immune Pathway Genes

Logan K. Wallace, MSc¹^*, Jack H. Peplinski, MSc¹^*, Rhonda E. Ries, MA¹^*, Danielle C. Kirkey, MD¹, Xiaotu Ma, PhD² and Soheil Meshinchi, MD, PhD^1,3

¹Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
²St. Jude Children's Research Hospital, Memphis, TN
³Department of Pediatrics, University of Washington, Seattle, WA

5:00 PM

639

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Yotaro Ochi, MD, PhD^1,2^*, Markus Liew-Littorin³^*, Yasuhito Nannya^1,4^*, Sofia Bengtzén⁵^*, Petar Antunovic⁶^*, Stefan Deneberg, MD⁵^*, Martin Jadersten, MD, PhD⁵^*, Vladimir Lazarevic^7,8^*, Bertil Uggla³^*, Lovisa Wennström, MD, PhD⁹^*, Emma Olander¹⁰^*, Senji Kasahara¹¹^*, Nobuhiro Hiramoto¹²^*, Nobuhiro Kanemura, MD, PhD¹³, Nobuo Sezaki¹⁴^*, Maki Sakurada¹⁵^*, Makoto Iwasaki, MD, PhD¹⁵, Junya Kanda, MD, PhD¹⁵^*, Yasunori Ueda¹⁶^*, Satoshi Yoshihara, MD, PhD¹⁷, Tom Erkers¹⁸^*, Nona Struyf¹⁸^*, Masanori Motomura, MD¹^*, Masahiro M Nakagawa, MD, PhD¹, Ryunosuke Saiki, MD, PhD¹^*, Hidehito Fukushima, MD⁴^*, Koji Okazaki, MD¹^*, Akinori Yoda, PhD¹^*, Rurika Okuda, MSc, BS¹^*, Guoxiang Xie¹⁹^*, Albin Osterroos, MD¹⁹^*, Lanying Zhao, MD, PhD¹^*, Yuichi Shiraishi, PhD²⁰^*, Takayuki Ishikawa, MD, PhD¹², Satoru Miyano, PhD^21,22^*, Hiroshi I Suzuki^23,24,25,26^*, Akifumi Takaori-Kondo, MD, PhD¹⁵, Olli Kallioniemi¹⁸^*, Gunnar Juliusson, MD, PhD^7,8, Martin Höglund, MD, PhD¹⁹, Soren Lehmann, MD, PhD^5,19^* and Seishi Ogawa, MD, PhD^1,2,27

¹Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
²Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
³Division of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
⁴Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
⁵Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
⁶Department of Hematology, Linköping University Hospital, Linköping, Sweden
⁷Department of Hematology, Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden
⁸Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
⁹Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
¹⁰Department of Hematology, Sundsvall Hospital, Sundsvall, Sweden
¹¹Department of Hematology, Gifu Municipal Hospital, Gifu, Japan
¹²Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
¹³Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan
¹⁴Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan
¹⁵Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
¹⁶Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan
¹⁷Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan
¹⁸Science for Life Laboratory and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
¹⁹Department of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden
²⁰Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan
²¹Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
²²Department of Integrated Analytics, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
²³Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
²⁴Institute for Glyco-core Research (iGCORE), Nagoya University, Nagoya, Japan
²⁵Center for One Medicine Innovative Translational Research (COMIT), Nagoya University, Nagoya, Japan
²⁶Inamori Research Institute for Science (InaRIS), Kyoto, Japan
²⁷Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden

5:15 PM

640

Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia

Maddalena Benetton¹^*, Ambra Da Ros¹^*, Alberto Peloso¹^*, Giorgia Longo¹^*, Katia Polato¹^*, Sara Perpinello¹^*, Silvia Bresolin²^*, Claudia Tregnago¹^*, Benjamin J Huang, MD³, Soheil Meshinchi, MD, PhD⁴, Franco Locatelli, MD⁵ and Martina Pigazzi, PhD^1,2^*

¹Department of Women's and Children's Health, Onco-hematology lab and clinic, University of Padova, Padova, Italy
²Foundation Istituto Ricerca Pediatrica (IRP), Padova, Italy
³Department of Pediatrics, University of California, San Francisco, San Francisco, CA
⁴Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
⁵Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Catholic University of the Sacred Heart, Rome, Italy

5:30 PM

641

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Lorenz Oelschläger¹, Deedra Nicolet, MS²^*, Krzysztof Mrózek, MD, PhD², Daniel Schnell³^*, Najla Alotaibi⁴^*, Christopher J. Walker, PhD⁴, Alice Mims, MD⁴, James S. Blachly, MD⁴, Bayard L Powell, MD⁵, Jonathan E Kolitz, MD⁶, Eunice S. Wang, MD⁷, Andrew J. Carroll, PhD⁸, Lynn van Rosmalen^9,10^*, Bettina Nadorp, PhD^11,12^*, Nathan Salomonis, PhD³^*, H. Leighton Grimes, PhD¹, Maarten Fornerod, PhD^9,13^* and Ann-Kathrin Eisfeld, MD²

¹Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH
²The Ohio State University Comprehensive Cancer Center, Columbus, OH
³Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
⁴Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁵Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
⁶Zucker School of Medicine at Hofstra/Northwell, Zuckerberg Cancer Center, Lake Success, NY
⁷Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁸Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
⁹Department of Cell Biology, Erasmus Medical Center, Rotterdam, Netherlands
¹⁰Department of Pediatric Oncology Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands
¹¹NYU Grossman School of Medicine, Division of Precision Medicine, Department of Medicine, New York, NY
¹²NYU Grossman School of Medicine, Department of Pathology, New York, NY
¹³Department of Pediatric Oncology Hematology,, Erasmus Medical Center- Sophia Childrens Hospital, Rotterdam, ZH, NLD

5:45 PM

642

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies

Sven Turkalj¹^*, Bilyana Stoilova, PhD²^*, Angus J Groom, MSc²^*, Felix A Radtke, MD², Rabea Mecklenbrauck, MD²^*, Niels Asger Jakobsen, MD, PhD²^*, Curtis A Lachowiez, MD³, Marlen Metzner, MSc²^*, Batchimeg Usukhbayar, PhD²^*, Mirian Angulo Salazar, MSc²^*, Zhihong Zeng, MD⁴, Sanam Loghavi, MD⁵, Jennifer Marvin-Peek, MD⁴, Verena Körber, PhD²^*, Farhad Ravandi, MBBS⁶, Ghayas C. Issa, MD⁴, Tapan M. Kadia, MD⁴, Vasiliki Symeonidou, PhD²^*, Anne De Groot, MSc²^*, Hagop M. Kantarjian, MD⁴, Koichi Takahashi, MD, PhD⁴, Marina Konopleva⁷, Courtney D. DiNardo, MD, MSc⁴ and Paresh Vyas, FMedSci, DPhil, FRCPath²^*

¹MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, ENG, United Kingdom
²MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom
³Knight Cancer Institute, Oregon Health & Science University, Portland, OR
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
⁷Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

618.O2.6 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis